Fatty acids don't reduce atrial fibrillation recurrence

Fatty acids don't reduce atrial fibrillation recurrence
Polyunsaturated fatty acids do not reduce the recurrence of atrial fibrillation, according to a study published online Dec. 19 in the Journal of the American College of Cardiology.

(HealthDay)—Polyunsaturated fatty acids (n-3 PUFA) do not reduce the recurrence of atrial fibrillation (AF), according to a study published online Dec. 19 in the Journal of the American College of Cardiology.

Alejandro Macchia, M.D., from Grupo de Estudio de Investigacion Clinica en Argentina in Buenos Aires, and colleagues randomly assigned outpatients with confirmed symptomatic paroxysmal AF that required cardioversion (428 patients), at least two episodes of AF in the six months before randomization (55), or both (103), to receive n-3 PUFA (1 g/day) or placebo for 12 months.

The researchers found that, for symptomatic recurrence of AF, there was no significant difference between the two groups, with 56 of 297 participants (18.9 percent) in the and 69 of 289 participants (24.0 percent) in the n-3 PUFA group having recurrent symptomatic AF (hazard ratio, 1.28; P = 0.17). There was also no difference between the two groups for the composite of all-cause mortality, nonfatal stroke, nonfatal , systemic embolism, heart failure development, or severe bleeding. The composite end point occurred in 20 patients (6.7 percent) and 16 patients (5.5 percent) randomized to placebo or n-3 PUFA, respectively (hazard ratio, 0.86; P = 0.65).

"Pharmacological supplementation with 1 g of n-3 PUFA for one year did not reduce recurrent AF," the authors write.

The study was funded by the Società Prodotti Antibiotici and Sigma Tau Pharmaceuticals, both of which provided the study drugs.

More information: Abstract
Full Text

add to favorites email to friend print save as pdf

Related Stories

The Medical Minute: Atrial Fibrillation -- What is It?

Oct 06, 2011

Atrial fibrillation (AF) is the most common heart rhythm disturbance in the United States and affects 2 to 4 million Americans. It is usually a disease of aging, however it can affect people of all ages -- 1 percent of people ...

Recommended for you

Vitamin K antagonist plus clopidogrel feasible for PCI

Sep 19, 2014

(HealthDay)—Vitamin K antagonists (VKA) combined with clopidogrel may be a better alternative to triple anticoagulant therapy in patients on long-term VKA undergoing percutaneous coronary intervention (PCI) ...

How pneumonia bacteria can compromise heart health

Sep 19, 2014

Bacterial pneumonia in adults carries an elevated risk for adverse cardiac events (such as heart failure, arrhythmias, and heart attacks) that contribute substantially to mortality—but how the heart is ...

An autoimmune response may contribute to hypertension

Sep 17, 2014

High blood pressure is a major risk factor for heart attack, stroke, chronic heart failure, and kidney disease. Inflammation is thought to promote the development of high blood pressure, though it is not clear what triggers ...

User comments